AstraZeneca share price logo

AstraZeneca

NYSE: AZN

Mega Cap

$158.61

+2.08

(+1.33%)

as on

AstraZeneca Stock Performance

as on October 7, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $156.26
    $159.96
    downward going graph

    1.48%

    Downside

    0.85%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $153.41
    $212.71
    downward going graph

    3.28%

    Downside

    34.11%

    Upside

    downward going graph

AstraZeneca share price movements today

Previous Close
$156.53
Open
$159.79
Volume
1.4M
Market Cap
$243.4B
Dividend Yield
2.06%
Day's Low - High
$156.26 - $159.96
52 Week Low - High
$153.41 - $212.71

AstraZeneca Historical Returns

1 Month Return
-2.51 %
3 Month Return
-17.87 %
1 Year Return
-7.65 %
3 Year Return
+ 17.63 %
5 Year Return
+ 31.36 %

AstraZeneca Stock Fundamentals & Key Indicators

Check AstraZeneca market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$243.4B

EPS (TTM)

6.71

Dividend Yield

2.06%

Quarterly Earnings Growth YOY

0.03%

PE Ratio (TTM)

23.17

Industry PE ratio

27.11

PEG Ratio

0.99

EBITDA

20.4B

Revenue (TTM)

61.3B

Profit Margin

79.27%

Return On Equity TTM

21.68%

AstraZeneca vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of AstraZeneca with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
AstraZeneca image
AstraZeneca
StrongBuy$243.4B31.36%23.1779.27%2.06%
Eli Lilly & Co image
Eli Lilly & Co
StrongBuy$1.1T396.39%38.2483.40%0.58%
AbbVie image
AbbVie
StrongBuy$464.4B140.54%74.8771.48%2.57%
Johnson & Johnson image
Johnson & Johnson
StrongBuy$617.0B57.91%29.2467.91%2.09%
Merck & Company image
Merck & Company
Buy$356.0B73.22%110.7575.38%2.44%

Stock Returns calculator for AstraZeneca Stock including INR - Dollar returns

The AstraZeneca stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

AstraZeneca investment value today

Current value as on today

₹1,00,369

Returns

₹369

(+0.37%)

Returns from AstraZeneca Stock

-₹7,645 (-7.65%)

Dollar Impact

₹8,014 (+8.01%)

Analyst Recommendation on AstraZeneca Stock

Based on 8 analysts

BUY

75.00%

Buy

25.00%

Hold

0.00%

Sell

Based on 8 analysts, 75% of analysts recommend a 'BUY' rating for AstraZeneca. Average target price of $211.35

AstraZeneca Share Price Target

Get share price movements and forecasts by analysts on AstraZeneca.

What analysts predicted

24.95%UPSIDE

Target Price

$211.35

Current Price

$158.61

Analyzed by

8 Analysts

High

$267.07026

Target

$211.35

Low

$154.68921

AstraZeneca target price $211.35, a slight upside of 24.95% compared to current price of $158.61. According to 8 analysts rating.

Indian Investors' Interest in AstraZeneca Stock

Investment in AstraZeneca Shares on INDmoney has dropped by -12.78% in the last 30 days, indicating reduced investment activity.

Time period: to

Change:-12.78% versus previous 30 day period

Search interest for AstraZeneca Stock has decreased by -14% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-14% versus previous 30 day period

AstraZeneca Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
12,550
12,978
13,964
14,537
13,959
14,843
15,191
15,503
15,288
15,291
Gross Profit
9,439
9,823
9,926
9,845
10,671
11,158
12,329
12,385
12,610
11,246
Operating Income
3,212
2,848
2,868
1,987
3,782
3,506
3,583
2,978
4,246
3,093
EBITDA
4,435
4,137
4,227
4,331
5,179
5,097
5,142
4,624
5,673
5,010
Interest Expense
408
444
470
418
358
450
434
484
393
432
Depreciation
1,242
1,283
1,870
2,281
1,319
1,426
1,549
1,511
1,366
1,917
Income Before Tax
2,771
2,404
1,881
1,626
3,494
3,210
3,244
2,629
3,914
2,782
Income Tax Expense
613
470
406
162
494
697
709
300
833
289
Net Income
2,156
1,933
1,471
1,464
2,995
2,515
2,533
2,326
3,080
2,491
Net Profit Margin
75.21%
75.69%
71.08%
67.73%
76.45%
75.17%
81.16%
79.89%
82.48%
73.55%

AstraZeneca Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
23,451
20,985
24,499
29,270
37,107
44,253
46,583
52,943
58,739
Gross Profit
17,378
15,062
17,725
21,662
22,599
28,040
34,447
39,698
48,106
Operating Income
3,623
1,744
2,820
4,969
2,809
5,048
9,569
12,521
13,743
EBITDA
5,636
5,344
5,242
8,035
4,585
8,629
13,195
14,858
19,829
Interest Expense
693
703
775
780
759
887
1,151
1,361
1,694
Depreciation
2,560
2,640
2,795
3,071
4,023
5,242
5,017
4,959
5,733
Income Before Tax
2,324
1,893
1,555
4,153
-259
2,495
7,015
8,509
12,402
Income Tax Expense
-669
-54
322
818
-372
-790
953
1,615
2,169
Net Income
3,132
2,047
1,341
3,390
109
3,280
6,055
6,888
10,225
Net Profit Margin
74.11%
71.78%
72.35%
74.01%
60.90%
63.36%
73.95%
74.98%
81.90%

AstraZeneca Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
2,800
2,397
1,828
1,666
2,916
3,127
2,533
2,629
3,914
2,491
Operating Cash Flow
2,486
3,085
3,383
2,907
3,713
3,386
5,134
2,342
3,359
2,905
Investing Cash Flow
-2,413
-2,872
-1,514
-1,181
-1,253
-2,108
-2,001
-1,446
-1,792
-2,949
Financing Cash Flow
2,028
-1,222
-4,131
-671
-2,707
518
-2,073
-3,282
267
-2,570
Change in Cash
2,055
-1,015
-2,242
994
-222
1,825
1,048
-2,382
1,816
-2,730

AstraZeneca Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
2,227
1,993
1,548
3,916
-265
2,501
6,899
8,691
12,402
Operating Cash Flow
3,578
2,618
2,969
4,799
5,963
9,808
10,345
11,861
14,575
Investing Cash Flow
-2,328
963
-657
-285
-11,058
-2,960
-4,064
-7,980
-6,808
Financing Cash Flow
-2,936
-2,044
-1,765
-2,203
3,649
-6,823
-6,567
-3,996
-7,544
Change in Cash
-1,752
1,499
552
2,323
-1,508
-55
-346
-208
269

Global Institutional Holdings in AstraZeneca

Check out the Institutions with significant holdings in AstraZeneca.

Funds
Holdings
iShares
5.04%
Vanguard
3.83%
VANGUARD STAR FUNDS
1.41%
UBS
1.38%
Theofanis Kolokotrones
1.17%
See all

AstraZeneca News & Key Events

  • img

    Today's Timeline - 05 October

    Mon, 05:05 PM

    -

    AstraZeneca completes $2 billion equity investment in Summit Therapeutics to accelerate ivonescimab development.

    Mon, 11:22 PM

    -

    AstraZeneca opens a $1 billion R&D center in Massachusetts, expanding workforce by over 50%.

    Tue, 01:14 AM

    -

    AstraZeneca CEO discusses Summit's ivonescimab as a potential future cancer treatment.

Insights on AstraZeneca

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    AstraZeneca PLC has seen steady revenue growth over the last two quarters, increasing from $15.28 billion to $15.38 billion. This reflects an average revenue increase of 0.6% per quarter.

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Eli Lilly & Co. has given 36.6% return, outperforming this stock by 19.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Merck & Co., Inc. has given 62.0% return, outperforming this stock by 69.6%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    AstraZeneca PLC has experienced a decline in net profit for the last two quarters. The profits fell from $3.08 billion to $2.50 billion, showing an average decrease of 18.6% per quarter.

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, AZN stock has moved down by -1.8%

About AstraZeneca

AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, key marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For cardiovascular, renal, and metabolism diseases, the company offers treatments such as Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR. Respiratory and immunology conditions are targeted by products like Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris. Additionally, rare diseases are treated with Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris. The company's product offerings also extend to Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for influenza; Seroquel IR/Seroquel XR for schizophrenia and bipolar disorder; Nexium and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for COVID-19. AstraZeneca serves primary and specialty care physicians globally, leveraging a network of distributors and local representative offices across the United Kingdom, the rest of Europe, the Americas, Asia, Africa, and Australasia. Strategic collaboration forms a vital component of its operations. Partnerships include an agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG for the development and commercialization of NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for transthyretin amyloidosis; Proteros Biostructures GmbH for the joint discovery of novel small molecules targeting hematological cancers; and Sierra Oncology, Inc. for the development and commercialization of AZD5153. Initially incorporated in 1992 as Zeneca Group PLC, the company adopted its current name, AstraZeneca PLC, in April 1999. It is headquartered in Cambridge, United Kingdom.
OrganisationAstraZeneca
Headquarters1 Francis Crick Avenue, Cambridge, CA, CB2 0AA, GB
IndustryDrug Manufacturers - General
CEOPascal Claude Roland Soriot

Key Management of AstraZeneca

Name

Title

Mr. Joris Silon

Head of Investor Relations

Dr. Ruud Dobber Ph.D.

Executive Vice-President of BioPharmaceuticals Business Unit

Ms. Ruth March FMEDSCI, O.B.E., Ph.D.

Senior VP of Precision Medicine - R&D Oncology

Ms. Pam P. Cheng

EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board

Dr. Aradhana Sarin M.D.

CFO & Executive Director

Mr. Jeffrey Pott J.D.

CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board

Dr. Susan Mary Galbraith M.D., Ph.D.

Executive Vice President of Oncology R&D

Ms. Iskra Reic

Executive Vice President of International

Mr. David Fredrickson

Executive Vice-President of Oncology Haematology Business Unit

Mr. Pascal Claude Roland Soriot D.V.M., M.B.A.

CEO & Executive Director

FAQs

What is AstraZeneca share price today?

AstraZeneca share price today is $158.61 as on at the close of the market. AstraZeneca share today touched a day high of $159.96 and a low of $156.26.

What is the 52 week high and 52 week low for AstraZeneca share?

AstraZeneca share touched a 52 week high of $212.71 on and a 52 week low of $153.41 on . AstraZeneca stock price today i.e. is closed at $158.61,which is 25.43% down from its 52 week high and 3.39% up from its 52 week low.

What is AstraZeneca's market capitalisation today?

AstraZeneca market capitalisation is $0.24T as on .

How to invest in AstraZeneca Stock (AZN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for AstraZeneca on INDmoney app. Click on Buy button.

What is the minimum amount required to buy AstraZeneca Stock (AZN) from India?

Indian investors can start investing in AstraZeneca (AZN) shares with as little as ₹96.419998168945 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹964.20 in AstraZeneca stock (as per the Rupee-Dollar exchange rate as on ). Based on AstraZeneca share’s latest price of $158.61 as on October 7, 2026 at 8:45 am IST, you will get 0.0630 shares of AstraZeneca. Learn more about fractional shares .

What are the returns that AstraZeneca has given to Indian investors in the last 5 years?

AstraZeneca stock has given 31.36% share price returns and 28.78% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?